Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that two oral presentations featuring DAYBUE™ (trofinetide) findings in Rett syndrome will be presented at the American Academy of Neurology (AAN) 2024 annual meeting, being held this week in Denver, CO.
The presentations include outcomes from the DAFFODIL™, a Phase 2/3 open-label study evaluating the safety, tolerability and exploratory efficacy of DAYBUE in girls aged two to four living with Rett syndrome, as well as findings from exit interviews with caregivers of individuals living with Rett syndrome who participated in the LAVENDER™, LILAC™, LILAC-2™ and DAFFODIL studies.
AAN Oral Presentations:
- Oral Presentation 003/Abstract 3540: Trofinetide for the Treatment of Girls Aged Two to Four Years with Rett Syndrome: Final Results from the Open-label DAFFODIL Study, Wednesday, April 17 at 3:54pm MT
- Oral Presentation 008/Abstract 2877: Assessing Experiences with Trofinetide for Rett Syndrome: Interviews with Caregivers of Patients in Open-label Studies, Wednesday, April 17 at 4:54pm MT
https://www.businesswire.com/news/home/20240417338314/en/
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide)...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.20 |
Change
-0.050(0.26%) |
Mkt cap ! $2.451B | |||
| Open | High | Low | Value | Volume |
| $19.16 | $19.44 | $19.06 | $4.162M | 216.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3727 | $19.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.27 | 399 | 1 |
View Market Depth
| Last trade - 16.10pm 30/04/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.26 |
Change
-0.050 ( 0.17 %) |
||||
| Open | High | Low | Volume | ||
| $19.22 | $19.43 | $19.05 | 52522 | ||
| Last updated 15.59pm 30/04/2024 ? | |||||
| NEU (ASX) Chart |